FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?
Oncotarget. 2021 May 25;12(11):1026-1028. doi: 10.18632/oncotarget.27957. eCollection 2021 May 25.NO ABSTRACTPMID:34084275 | PMC:PMC8169064 | DOI:10.18632/oncotarget.27957 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Leandro H Gallo Source Type: research

Advances in innovative exosome-technology for real time monitoring of viable drugs in clinical translation, prognosis and treatment response
Oncotarget. 2021 May 25;12(11):1029-1031. doi: 10.18632/oncotarget.27927. eCollection 2021 May 25.NO ABSTRACTPMID:34084276 | PMC:PMC8169069 | DOI:10.18632/oncotarget.27927 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Mujib Ullah Nicole Pek Min Qian Gustavo Yannarelli Source Type: research

Drug-development, dose-selection, rational combinations from bench-to-bedside: are there any lessons worth revisiting?
Oncotarget. 2021 May 25;12(11):1032-1036. doi: 10.18632/oncotarget.27931. eCollection 2021 May 25.NO ABSTRACTPMID:34084277 | PMC:PMC8169070 | DOI:10.18632/oncotarget.27931 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Alexander J Bridges Ranjit K Mehta Sushmita Shukla Matthew J Schipper Theodore S Lawrence Mukesh K Nyati Source Type: research

CEA as a blood-based biomarker in anal cancer
CONCLUSIONS: Despite interesting patterns of abnormally high CEA in SCCA patients with advanced disease, and correlation of increased CEA with disease progression (and conversely decreased CEA with disease response), CEA is not associated with survival outcomes in SCCA, and is not a clinically relevant biomarker in this disease.PMID:34084278 | PMC:PMC8169063 | DOI:10.18632/oncotarget.27959 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Robert Hester Shailesh Advani Asif Rashid Emma Holliday Craig Messick Prajnan Das Yi-Qian N You Cullen Taniguchi Eugene J Koay Brian Bednarski Miguel Rodriguez-Bigas John Skibber Robert Wolff George J Chang Bruce D Minsky Wai Chin Foo Nicole Rothschild Va Source Type: research

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
CONCLUSIONS: Most of mCRC patients treated with bevacizumab-containing regimens experience a strong reduction of RAS mutant cells, suggesting bevacizumab as particularly active against RAS mutant cells. This finding might have potential therapeutic implications, as anti-EGFR could be reconsidered in primarily RAS mutant patients reverted to a wild-type status after bevacizumab exposure.PMID:34084279 | PMC:PMC8169066 | DOI:10.18632/oncotarget.27965 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Samantha Epistolio Marco Cefal ì Paolo Spina Francesca Molinari Alessandra Movilia Massimiliano Cergnul Luca Mazzucchelli Sara De Dosso Milo Frattini Piercarlo Saletti Source Type: research

Caspase-11 and AIM2 inflammasome are involved in smoking-induced COPD and lung adenocarcinoma
Oncotarget. 2021 May 25;12(11):1057-1071. doi: 10.18632/oncotarget.27964. eCollection 2021 May 25.ABSTRACTCigarette smoking is the leading risk factor for COPD and lung cancer establishment. Epidemiologically, COPD patients are 6.35 times more likely to develop lung cancer. To mimic COPD, we exposed mice to nose-only cigarette smoke and used human samples of lung adenocarcinoma patients according to the smoking and COPD status. Smoking C57Bl/6N mice had higher enlargement of alveoli, deposition of collagen and mucus production, associated to the release of IL-1-like cytokines, such as IL-1α and IL-1β at early ti...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Chiara Colarusso Michela Terlizzi Anne-Sophie Lamort Ida Cerqua Fiorentina Roviezzo Georgios Stathopoulos Aldo Pinto Rosalinda Sorrentino Source Type: research

A novel E2F1-regulated lncRNA, LAPAS1, is required for S phase progression and cell proliferation
Oncotarget. 2021 May 25;12(11):1072-1082. doi: 10.18632/oncotarget.27962. eCollection 2021 May 25.ABSTRACTThe transcription factor E2F1 induces both proliferation and apoptosis and is a critical downstream target of the tumor suppressor RB. Long non-coding RNAs (lncRNAs) are major regulators of many cellular processes, including cell cycle progression and cell proliferation. However, the mode of action as well as the transcriptional regulation of most lncRNAs are only beginning to be understood. Here, we report that a novel human lncRNA, LAPAS1, is an E2F1- regulated lncRNA that affects S phase progression. Inhibition of L...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Esther Baruch Tali Nizri-Megnaji Oron Berkowitz Doron Ginsberg Source Type: research

Epigallocatechin-3-gallate modulates Tau Post-translational modifications and cytoskeletal network
CONCLUSIONS: We report EGCG, a green tea polyphenol, as a modulator of in vitro methylglyoxal-induced Tau glycation and its impact on reducing advanced glycation end products in neuroblastoma cells. We unravel unprecedented function of EGCG in remodeling neuronal cytoskeletal integrity.PMID:34084282 | PMC:PMC8169072 | DOI:10.18632/oncotarget.27963 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Shweta Kishor Sonawane Subashchandrabose Chinnathambi Source Type: research

< em > Ex vivo < /em > analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma
Oncotarget. 2021 May 25;12(11):1100-1109. doi: 10.18632/oncotarget.27961. eCollection 2021 May 25.ABSTRACTCutaneous apocrine carcinoma is an extreme rare malignancy derived from a sweat gland. Histologically sweat gland cancers resemble metastatic mammary apocrine carcinomas, but the genetic landscape remains poorly understood. Here, we report a rare metastatic case with a PALB2 aberration identified previously as a familial susceptibility gene for breast cancer in the Finnish population. As PALB2 exhibits functions in the BRCA1/2-RAD51-dependent homologous DNA recombination repair pathway, we sought to use ex vivo functio...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Rami M äkelä Ville H ärmä Nibal Badra Fajardo Greg Wells Zoi Lygerou Olle Sangfelt Juha Kononen Juha K Rantala Source Type: research

Evaluation of liver kinase B1 downstream signaling expression in various breast cancers and relapse free survival after systemic chemotherapy treatment
This report evaluates LKB1-signaling pathway gene expression associations with patient survival in overall breast cancer, specific subtypes, as well as pre- and post-chemotherapy. Subtypes analyzed were based on intrinsic molecular subtyping and traditional biomarker classifications. Intrinsic molecular subtypes included were Luminal-A, Luminal-B, HER2-enriched, and Basal-like. The biomarker subtypes assessed were Estrogen-Receptor Positive (ER+) and Negative (ER-), Wild-Type TP53 (WT-TP53) & Mutant-TP53, and Triple-Negative Breast Cancer (TNBC). Additionally, comparisons were made between these subtypes and breast can...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Khoa Nguyen Andrew Rivera Madlin Alzoubi Henri Wathieu Shengli Dong Hassan Yousefi Margarite Matossian Suresh Alahari David Drewry Matthew Burow Bridgette Collins-Burow Source Type: research

Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
Oncotarget. 2021 May 25;12(11):1116-1121. doi: 10.18632/oncotarget.27966. eCollection 2021 May 25.ABSTRACTXeroderma Pigmentosum (XP) is a rare genetic disorder with a poor prognosis due to high photosensitivity in affected patients. Herein, we describe the first case of the use of cemiplimab in a patient with XP, a 19-year-old girl presented with locally advanced squamous cell carcinoma of the right periorbital and nasal region. This treatment has been undertaken after a cycle of proton beam radiotherapy. Besides, it is reported a description of the few cases in the literature describing the effectiveness of immunotherapy ...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Marco Rubatto Martina Merli Gianluca Avallone Andrea Agostini Luca Mastorino Virginia Caliendo Amelia Barcellini Viviana Vitolo Francesca Valvo Maria Teresa Fierro Simone Ribero Pietro Quaglino Source Type: research

FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?
Oncotarget. 2021 May 25;12(11):1026-1028. doi: 10.18632/oncotarget.27957. eCollection 2021 May 25.NO ABSTRACTPMID:34084275 | PMC:PMC8169064 | DOI:10.18632/oncotarget.27957 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Leandro H Gallo Source Type: research

Advances in innovative exosome-technology for real time monitoring of viable drugs in clinical translation, prognosis and treatment response
Oncotarget. 2021 May 25;12(11):1029-1031. doi: 10.18632/oncotarget.27927. eCollection 2021 May 25.NO ABSTRACTPMID:34084276 | PMC:PMC8169069 | DOI:10.18632/oncotarget.27927 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Mujib Ullah Nicole Pek Min Qian Gustavo Yannarelli Source Type: research

Drug-development, dose-selection, rational combinations from bench-to-bedside: are there any lessons worth revisiting?
Oncotarget. 2021 May 25;12(11):1032-1036. doi: 10.18632/oncotarget.27931. eCollection 2021 May 25.NO ABSTRACTPMID:34084277 | PMC:PMC8169070 | DOI:10.18632/oncotarget.27931 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Alexander J Bridges Ranjit K Mehta Sushmita Shukla Matthew J Schipper Theodore S Lawrence Mukesh K Nyati Source Type: research

CEA as a blood-based biomarker in anal cancer
CONCLUSIONS: Despite interesting patterns of abnormally high CEA in SCCA patients with advanced disease, and correlation of increased CEA with disease progression (and conversely decreased CEA with disease response), CEA is not associated with survival outcomes in SCCA, and is not a clinically relevant biomarker in this disease.PMID:34084278 | PMC:PMC8169063 | DOI:10.18632/oncotarget.27959 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Robert Hester Shailesh Advani Asif Rashid Emma Holliday Craig Messick Prajnan Das Yi-Qian N You Cullen Taniguchi Eugene J Koay Brian Bednarski Miguel Rodriguez-Bigas John Skibber Robert Wolff George J Chang Bruce D Minsky Wai Chin Foo Nicole Rothschild Va Source Type: research

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
CONCLUSIONS: Most of mCRC patients treated with bevacizumab-containing regimens experience a strong reduction of RAS mutant cells, suggesting bevacizumab as particularly active against RAS mutant cells. This finding might have potential therapeutic implications, as anti-EGFR could be reconsidered in primarily RAS mutant patients reverted to a wild-type status after bevacizumab exposure.PMID:34084279 | PMC:PMC8169066 | DOI:10.18632/oncotarget.27965 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Samantha Epistolio Marco Cefal ì Paolo Spina Francesca Molinari Alessandra Movilia Massimiliano Cergnul Luca Mazzucchelli Sara De Dosso Milo Frattini Piercarlo Saletti Source Type: research

Caspase-11 and AIM2 inflammasome are involved in smoking-induced COPD and lung adenocarcinoma
Oncotarget. 2021 May 25;12(11):1057-1071. doi: 10.18632/oncotarget.27964. eCollection 2021 May 25.ABSTRACTCigarette smoking is the leading risk factor for COPD and lung cancer establishment. Epidemiologically, COPD patients are 6.35 times more likely to develop lung cancer. To mimic COPD, we exposed mice to nose-only cigarette smoke and used human samples of lung adenocarcinoma patients according to the smoking and COPD status. Smoking C57Bl/6N mice had higher enlargement of alveoli, deposition of collagen and mucus production, associated to the release of IL-1-like cytokines, such as IL-1α and IL-1β at early ti...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Chiara Colarusso Michela Terlizzi Anne-Sophie Lamort Ida Cerqua Fiorentina Roviezzo Georgios Stathopoulos Aldo Pinto Rosalinda Sorrentino Source Type: research

A novel E2F1-regulated lncRNA, LAPAS1, is required for S phase progression and cell proliferation
Oncotarget. 2021 May 25;12(11):1072-1082. doi: 10.18632/oncotarget.27962. eCollection 2021 May 25.ABSTRACTThe transcription factor E2F1 induces both proliferation and apoptosis and is a critical downstream target of the tumor suppressor RB. Long non-coding RNAs (lncRNAs) are major regulators of many cellular processes, including cell cycle progression and cell proliferation. However, the mode of action as well as the transcriptional regulation of most lncRNAs are only beginning to be understood. Here, we report that a novel human lncRNA, LAPAS1, is an E2F1- regulated lncRNA that affects S phase progression. Inhibition of L...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Esther Baruch Tali Nizri-Megnaji Oron Berkowitz Doron Ginsberg Source Type: research

Epigallocatechin-3-gallate modulates Tau Post-translational modifications and cytoskeletal network
CONCLUSIONS: We report EGCG, a green tea polyphenol, as a modulator of in vitro methylglyoxal-induced Tau glycation and its impact on reducing advanced glycation end products in neuroblastoma cells. We unravel unprecedented function of EGCG in remodeling neuronal cytoskeletal integrity.PMID:34084282 | PMC:PMC8169072 | DOI:10.18632/oncotarget.27963 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Shweta Kishor Sonawane Subashchandrabose Chinnathambi Source Type: research

< em > Ex vivo < /em > analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma
Oncotarget. 2021 May 25;12(11):1100-1109. doi: 10.18632/oncotarget.27961. eCollection 2021 May 25.ABSTRACTCutaneous apocrine carcinoma is an extreme rare malignancy derived from a sweat gland. Histologically sweat gland cancers resemble metastatic mammary apocrine carcinomas, but the genetic landscape remains poorly understood. Here, we report a rare metastatic case with a PALB2 aberration identified previously as a familial susceptibility gene for breast cancer in the Finnish population. As PALB2 exhibits functions in the BRCA1/2-RAD51-dependent homologous DNA recombination repair pathway, we sought to use ex vivo functio...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Rami M äkelä Ville H ärmä Nibal Badra Fajardo Greg Wells Zoi Lygerou Olle Sangfelt Juha Kononen Juha K Rantala Source Type: research

Evaluation of liver kinase B1 downstream signaling expression in various breast cancers and relapse free survival after systemic chemotherapy treatment
This report evaluates LKB1-signaling pathway gene expression associations with patient survival in overall breast cancer, specific subtypes, as well as pre- and post-chemotherapy. Subtypes analyzed were based on intrinsic molecular subtyping and traditional biomarker classifications. Intrinsic molecular subtypes included were Luminal-A, Luminal-B, HER2-enriched, and Basal-like. The biomarker subtypes assessed were Estrogen-Receptor Positive (ER+) and Negative (ER-), Wild-Type TP53 (WT-TP53) & Mutant-TP53, and Triple-Negative Breast Cancer (TNBC). Additionally, comparisons were made between these subtypes and breast can...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Khoa Nguyen Andrew Rivera Madlin Alzoubi Henri Wathieu Shengli Dong Hassan Yousefi Margarite Matossian Suresh Alahari David Drewry Matthew Burow Bridgette Collins-Burow Source Type: research

Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
Oncotarget. 2021 May 25;12(11):1116-1121. doi: 10.18632/oncotarget.27966. eCollection 2021 May 25.ABSTRACTXeroderma Pigmentosum (XP) is a rare genetic disorder with a poor prognosis due to high photosensitivity in affected patients. Herein, we describe the first case of the use of cemiplimab in a patient with XP, a 19-year-old girl presented with locally advanced squamous cell carcinoma of the right periorbital and nasal region. This treatment has been undertaken after a cycle of proton beam radiotherapy. Besides, it is reported a description of the few cases in the literature describing the effectiveness of immunotherapy ...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Marco Rubatto Martina Merli Gianluca Avallone Andrea Agostini Luca Mastorino Virginia Caliendo Amelia Barcellini Viviana Vitolo Francesca Valvo Maria Teresa Fierro Simone Ribero Pietro Quaglino Source Type: research

FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?
Oncotarget. 2021 May 25;12(11):1026-1028. doi: 10.18632/oncotarget.27957. eCollection 2021 May 25.NO ABSTRACTPMID:34084275 | PMC:PMC8169064 | DOI:10.18632/oncotarget.27957 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Leandro H Gallo Source Type: research

Advances in innovative exosome-technology for real time monitoring of viable drugs in clinical translation, prognosis and treatment response
Oncotarget. 2021 May 25;12(11):1029-1031. doi: 10.18632/oncotarget.27927. eCollection 2021 May 25.NO ABSTRACTPMID:34084276 | PMC:PMC8169069 | DOI:10.18632/oncotarget.27927 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Mujib Ullah Nicole Pek Min Qian Gustavo Yannarelli Source Type: research

Drug-development, dose-selection, rational combinations from bench-to-bedside: are there any lessons worth revisiting?
Oncotarget. 2021 May 25;12(11):1032-1036. doi: 10.18632/oncotarget.27931. eCollection 2021 May 25.NO ABSTRACTPMID:34084277 | PMC:PMC8169070 | DOI:10.18632/oncotarget.27931 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Alexander J Bridges Ranjit K Mehta Sushmita Shukla Matthew J Schipper Theodore S Lawrence Mukesh K Nyati Source Type: research

CEA as a blood-based biomarker in anal cancer
CONCLUSIONS: Despite interesting patterns of abnormally high CEA in SCCA patients with advanced disease, and correlation of increased CEA with disease progression (and conversely decreased CEA with disease response), CEA is not associated with survival outcomes in SCCA, and is not a clinically relevant biomarker in this disease.PMID:34084278 | PMC:PMC8169063 | DOI:10.18632/oncotarget.27959 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Robert Hester Shailesh Advani Asif Rashid Emma Holliday Craig Messick Prajnan Das Yi-Qian N You Cullen Taniguchi Eugene J Koay Brian Bednarski Miguel Rodriguez-Bigas John Skibber Robert Wolff George J Chang Bruce D Minsky Wai Chin Foo Nicole Rothschild Va Source Type: research

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
CONCLUSIONS: Most of mCRC patients treated with bevacizumab-containing regimens experience a strong reduction of RAS mutant cells, suggesting bevacizumab as particularly active against RAS mutant cells. This finding might have potential therapeutic implications, as anti-EGFR could be reconsidered in primarily RAS mutant patients reverted to a wild-type status after bevacizumab exposure.PMID:34084279 | PMC:PMC8169066 | DOI:10.18632/oncotarget.27965 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Samantha Epistolio Marco Cefal ì Paolo Spina Francesca Molinari Alessandra Movilia Massimiliano Cergnul Luca Mazzucchelli Sara De Dosso Milo Frattini Piercarlo Saletti Source Type: research

Caspase-11 and AIM2 inflammasome are involved in smoking-induced COPD and lung adenocarcinoma
Oncotarget. 2021 May 25;12(11):1057-1071. doi: 10.18632/oncotarget.27964. eCollection 2021 May 25.ABSTRACTCigarette smoking is the leading risk factor for COPD and lung cancer establishment. Epidemiologically, COPD patients are 6.35 times more likely to develop lung cancer. To mimic COPD, we exposed mice to nose-only cigarette smoke and used human samples of lung adenocarcinoma patients according to the smoking and COPD status. Smoking C57Bl/6N mice had higher enlargement of alveoli, deposition of collagen and mucus production, associated to the release of IL-1-like cytokines, such as IL-1α and IL-1β at early ti...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Chiara Colarusso Michela Terlizzi Anne-Sophie Lamort Ida Cerqua Fiorentina Roviezzo Georgios Stathopoulos Aldo Pinto Rosalinda Sorrentino Source Type: research

A novel E2F1-regulated lncRNA, LAPAS1, is required for S phase progression and cell proliferation
Oncotarget. 2021 May 25;12(11):1072-1082. doi: 10.18632/oncotarget.27962. eCollection 2021 May 25.ABSTRACTThe transcription factor E2F1 induces both proliferation and apoptosis and is a critical downstream target of the tumor suppressor RB. Long non-coding RNAs (lncRNAs) are major regulators of many cellular processes, including cell cycle progression and cell proliferation. However, the mode of action as well as the transcriptional regulation of most lncRNAs are only beginning to be understood. Here, we report that a novel human lncRNA, LAPAS1, is an E2F1- regulated lncRNA that affects S phase progression. Inhibition of L...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Esther Baruch Tali Nizri-Megnaji Oron Berkowitz Doron Ginsberg Source Type: research

Epigallocatechin-3-gallate modulates Tau Post-translational modifications and cytoskeletal network
CONCLUSIONS: We report EGCG, a green tea polyphenol, as a modulator of in vitro methylglyoxal-induced Tau glycation and its impact on reducing advanced glycation end products in neuroblastoma cells. We unravel unprecedented function of EGCG in remodeling neuronal cytoskeletal integrity.PMID:34084282 | PMC:PMC8169072 | DOI:10.18632/oncotarget.27963 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Shweta Kishor Sonawane Subashchandrabose Chinnathambi Source Type: research

< em > Ex vivo < /em > analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma
Oncotarget. 2021 May 25;12(11):1100-1109. doi: 10.18632/oncotarget.27961. eCollection 2021 May 25.ABSTRACTCutaneous apocrine carcinoma is an extreme rare malignancy derived from a sweat gland. Histologically sweat gland cancers resemble metastatic mammary apocrine carcinomas, but the genetic landscape remains poorly understood. Here, we report a rare metastatic case with a PALB2 aberration identified previously as a familial susceptibility gene for breast cancer in the Finnish population. As PALB2 exhibits functions in the BRCA1/2-RAD51-dependent homologous DNA recombination repair pathway, we sought to use ex vivo functio...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Rami M äkelä Ville H ärmä Nibal Badra Fajardo Greg Wells Zoi Lygerou Olle Sangfelt Juha Kononen Juha K Rantala Source Type: research

Evaluation of liver kinase B1 downstream signaling expression in various breast cancers and relapse free survival after systemic chemotherapy treatment
This report evaluates LKB1-signaling pathway gene expression associations with patient survival in overall breast cancer, specific subtypes, as well as pre- and post-chemotherapy. Subtypes analyzed were based on intrinsic molecular subtyping and traditional biomarker classifications. Intrinsic molecular subtypes included were Luminal-A, Luminal-B, HER2-enriched, and Basal-like. The biomarker subtypes assessed were Estrogen-Receptor Positive (ER+) and Negative (ER-), Wild-Type TP53 (WT-TP53) & Mutant-TP53, and Triple-Negative Breast Cancer (TNBC). Additionally, comparisons were made between these subtypes and breast can...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Khoa Nguyen Andrew Rivera Madlin Alzoubi Henri Wathieu Shengli Dong Hassan Yousefi Margarite Matossian Suresh Alahari David Drewry Matthew Burow Bridgette Collins-Burow Source Type: research

Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
Oncotarget. 2021 May 25;12(11):1116-1121. doi: 10.18632/oncotarget.27966. eCollection 2021 May 25.ABSTRACTXeroderma Pigmentosum (XP) is a rare genetic disorder with a poor prognosis due to high photosensitivity in affected patients. Herein, we describe the first case of the use of cemiplimab in a patient with XP, a 19-year-old girl presented with locally advanced squamous cell carcinoma of the right periorbital and nasal region. This treatment has been undertaken after a cycle of proton beam radiotherapy. Besides, it is reported a description of the few cases in the literature describing the effectiveness of immunotherapy ...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Marco Rubatto Martina Merli Gianluca Avallone Andrea Agostini Luca Mastorino Virginia Caliendo Amelia Barcellini Viviana Vitolo Francesca Valvo Maria Teresa Fierro Simone Ribero Pietro Quaglino Source Type: research

FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?
Oncotarget. 2021 May 25;12(11):1026-1028. doi: 10.18632/oncotarget.27957. eCollection 2021 May 25.NO ABSTRACTPMID:34084275 | PMC:PMC8169064 | DOI:10.18632/oncotarget.27957 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Leandro H Gallo Source Type: research

Advances in innovative exosome-technology for real time monitoring of viable drugs in clinical translation, prognosis and treatment response
Oncotarget. 2021 May 25;12(11):1029-1031. doi: 10.18632/oncotarget.27927. eCollection 2021 May 25.NO ABSTRACTPMID:34084276 | PMC:PMC8169069 | DOI:10.18632/oncotarget.27927 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Mujib Ullah Nicole Pek Min Qian Gustavo Yannarelli Source Type: research

Drug-development, dose-selection, rational combinations from bench-to-bedside: are there any lessons worth revisiting?
Oncotarget. 2021 May 25;12(11):1032-1036. doi: 10.18632/oncotarget.27931. eCollection 2021 May 25.NO ABSTRACTPMID:34084277 | PMC:PMC8169070 | DOI:10.18632/oncotarget.27931 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Alexander J Bridges Ranjit K Mehta Sushmita Shukla Matthew J Schipper Theodore S Lawrence Mukesh K Nyati Source Type: research

CEA as a blood-based biomarker in anal cancer
CONCLUSIONS: Despite interesting patterns of abnormally high CEA in SCCA patients with advanced disease, and correlation of increased CEA with disease progression (and conversely decreased CEA with disease response), CEA is not associated with survival outcomes in SCCA, and is not a clinically relevant biomarker in this disease.PMID:34084278 | PMC:PMC8169063 | DOI:10.18632/oncotarget.27959 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Robert Hester Shailesh Advani Asif Rashid Emma Holliday Craig Messick Prajnan Das Yi-Qian N You Cullen Taniguchi Eugene J Koay Brian Bednarski Miguel Rodriguez-Bigas John Skibber Robert Wolff George J Chang Bruce D Minsky Wai Chin Foo Nicole Rothschild Va Source Type: research

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
CONCLUSIONS: Most of mCRC patients treated with bevacizumab-containing regimens experience a strong reduction of RAS mutant cells, suggesting bevacizumab as particularly active against RAS mutant cells. This finding might have potential therapeutic implications, as anti-EGFR could be reconsidered in primarily RAS mutant patients reverted to a wild-type status after bevacizumab exposure.PMID:34084279 | PMC:PMC8169066 | DOI:10.18632/oncotarget.27965 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Samantha Epistolio Marco Cefal ì Paolo Spina Francesca Molinari Alessandra Movilia Massimiliano Cergnul Luca Mazzucchelli Sara De Dosso Milo Frattini Piercarlo Saletti Source Type: research

Caspase-11 and AIM2 inflammasome are involved in smoking-induced COPD and lung adenocarcinoma
Oncotarget. 2021 May 25;12(11):1057-1071. doi: 10.18632/oncotarget.27964. eCollection 2021 May 25.ABSTRACTCigarette smoking is the leading risk factor for COPD and lung cancer establishment. Epidemiologically, COPD patients are 6.35 times more likely to develop lung cancer. To mimic COPD, we exposed mice to nose-only cigarette smoke and used human samples of lung adenocarcinoma patients according to the smoking and COPD status. Smoking C57Bl/6N mice had higher enlargement of alveoli, deposition of collagen and mucus production, associated to the release of IL-1-like cytokines, such as IL-1α and IL-1β at early ti...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Chiara Colarusso Michela Terlizzi Anne-Sophie Lamort Ida Cerqua Fiorentina Roviezzo Georgios Stathopoulos Aldo Pinto Rosalinda Sorrentino Source Type: research

A novel E2F1-regulated lncRNA, LAPAS1, is required for S phase progression and cell proliferation
Oncotarget. 2021 May 25;12(11):1072-1082. doi: 10.18632/oncotarget.27962. eCollection 2021 May 25.ABSTRACTThe transcription factor E2F1 induces both proliferation and apoptosis and is a critical downstream target of the tumor suppressor RB. Long non-coding RNAs (lncRNAs) are major regulators of many cellular processes, including cell cycle progression and cell proliferation. However, the mode of action as well as the transcriptional regulation of most lncRNAs are only beginning to be understood. Here, we report that a novel human lncRNA, LAPAS1, is an E2F1- regulated lncRNA that affects S phase progression. Inhibition of L...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Esther Baruch Tali Nizri-Megnaji Oron Berkowitz Doron Ginsberg Source Type: research

Epigallocatechin-3-gallate modulates Tau Post-translational modifications and cytoskeletal network
CONCLUSIONS: We report EGCG, a green tea polyphenol, as a modulator of in vitro methylglyoxal-induced Tau glycation and its impact on reducing advanced glycation end products in neuroblastoma cells. We unravel unprecedented function of EGCG in remodeling neuronal cytoskeletal integrity.PMID:34084282 | PMC:PMC8169072 | DOI:10.18632/oncotarget.27963 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Shweta Kishor Sonawane Subashchandrabose Chinnathambi Source Type: research

< em > Ex vivo < /em > analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma
Oncotarget. 2021 May 25;12(11):1100-1109. doi: 10.18632/oncotarget.27961. eCollection 2021 May 25.ABSTRACTCutaneous apocrine carcinoma is an extreme rare malignancy derived from a sweat gland. Histologically sweat gland cancers resemble metastatic mammary apocrine carcinomas, but the genetic landscape remains poorly understood. Here, we report a rare metastatic case with a PALB2 aberration identified previously as a familial susceptibility gene for breast cancer in the Finnish population. As PALB2 exhibits functions in the BRCA1/2-RAD51-dependent homologous DNA recombination repair pathway, we sought to use ex vivo functio...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Rami M äkelä Ville H ärmä Nibal Badra Fajardo Greg Wells Zoi Lygerou Olle Sangfelt Juha Kononen Juha K Rantala Source Type: research

Evaluation of liver kinase B1 downstream signaling expression in various breast cancers and relapse free survival after systemic chemotherapy treatment
This report evaluates LKB1-signaling pathway gene expression associations with patient survival in overall breast cancer, specific subtypes, as well as pre- and post-chemotherapy. Subtypes analyzed were based on intrinsic molecular subtyping and traditional biomarker classifications. Intrinsic molecular subtypes included were Luminal-A, Luminal-B, HER2-enriched, and Basal-like. The biomarker subtypes assessed were Estrogen-Receptor Positive (ER+) and Negative (ER-), Wild-Type TP53 (WT-TP53) & Mutant-TP53, and Triple-Negative Breast Cancer (TNBC). Additionally, comparisons were made between these subtypes and breast can...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Khoa Nguyen Andrew Rivera Madlin Alzoubi Henri Wathieu Shengli Dong Hassan Yousefi Margarite Matossian Suresh Alahari David Drewry Matthew Burow Bridgette Collins-Burow Source Type: research

Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
Oncotarget. 2021 May 25;12(11):1116-1121. doi: 10.18632/oncotarget.27966. eCollection 2021 May 25.ABSTRACTXeroderma Pigmentosum (XP) is a rare genetic disorder with a poor prognosis due to high photosensitivity in affected patients. Herein, we describe the first case of the use of cemiplimab in a patient with XP, a 19-year-old girl presented with locally advanced squamous cell carcinoma of the right periorbital and nasal region. This treatment has been undertaken after a cycle of proton beam radiotherapy. Besides, it is reported a description of the few cases in the literature describing the effectiveness of immunotherapy ...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Marco Rubatto Martina Merli Gianluca Avallone Andrea Agostini Luca Mastorino Virginia Caliendo Amelia Barcellini Viviana Vitolo Francesca Valvo Maria Teresa Fierro Simone Ribero Pietro Quaglino Source Type: research

FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?
Oncotarget. 2021 May 25;12(11):1026-1028. doi: 10.18632/oncotarget.27957. eCollection 2021 May 25.NO ABSTRACTPMID:34084275 | PMC:PMC8169064 | DOI:10.18632/oncotarget.27957 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Leandro H Gallo Source Type: research

Advances in innovative exosome-technology for real time monitoring of viable drugs in clinical translation, prognosis and treatment response
Oncotarget. 2021 May 25;12(11):1029-1031. doi: 10.18632/oncotarget.27927. eCollection 2021 May 25.NO ABSTRACTPMID:34084276 | PMC:PMC8169069 | DOI:10.18632/oncotarget.27927 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Mujib Ullah Nicole Pek Min Qian Gustavo Yannarelli Source Type: research

Drug-development, dose-selection, rational combinations from bench-to-bedside: are there any lessons worth revisiting?
Oncotarget. 2021 May 25;12(11):1032-1036. doi: 10.18632/oncotarget.27931. eCollection 2021 May 25.NO ABSTRACTPMID:34084277 | PMC:PMC8169070 | DOI:10.18632/oncotarget.27931 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Alexander J Bridges Ranjit K Mehta Sushmita Shukla Matthew J Schipper Theodore S Lawrence Mukesh K Nyati Source Type: research

CEA as a blood-based biomarker in anal cancer
CONCLUSIONS: Despite interesting patterns of abnormally high CEA in SCCA patients with advanced disease, and correlation of increased CEA with disease progression (and conversely decreased CEA with disease response), CEA is not associated with survival outcomes in SCCA, and is not a clinically relevant biomarker in this disease.PMID:34084278 | PMC:PMC8169063 | DOI:10.18632/oncotarget.27959 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Robert Hester Shailesh Advani Asif Rashid Emma Holliday Craig Messick Prajnan Das Yi-Qian N You Cullen Taniguchi Eugene J Koay Brian Bednarski Miguel Rodriguez-Bigas John Skibber Robert Wolff George J Chang Bruce D Minsky Wai Chin Foo Nicole Rothschild Va Source Type: research

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
CONCLUSIONS: Most of mCRC patients treated with bevacizumab-containing regimens experience a strong reduction of RAS mutant cells, suggesting bevacizumab as particularly active against RAS mutant cells. This finding might have potential therapeutic implications, as anti-EGFR could be reconsidered in primarily RAS mutant patients reverted to a wild-type status after bevacizumab exposure.PMID:34084279 | PMC:PMC8169066 | DOI:10.18632/oncotarget.27965 (Source: Oncotarget)
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Samantha Epistolio Marco Cefal ì Paolo Spina Francesca Molinari Alessandra Movilia Massimiliano Cergnul Luca Mazzucchelli Sara De Dosso Milo Frattini Piercarlo Saletti Source Type: research

Caspase-11 and AIM2 inflammasome are involved in smoking-induced COPD and lung adenocarcinoma
Oncotarget. 2021 May 25;12(11):1057-1071. doi: 10.18632/oncotarget.27964. eCollection 2021 May 25.ABSTRACTCigarette smoking is the leading risk factor for COPD and lung cancer establishment. Epidemiologically, COPD patients are 6.35 times more likely to develop lung cancer. To mimic COPD, we exposed mice to nose-only cigarette smoke and used human samples of lung adenocarcinoma patients according to the smoking and COPD status. Smoking C57Bl/6N mice had higher enlargement of alveoli, deposition of collagen and mucus production, associated to the release of IL-1-like cytokines, such as IL-1α and IL-1β at early ti...
Source: Oncotarget - June 4, 2021 Category: Cancer & Oncology Authors: Chiara Colarusso Michela Terlizzi Anne-Sophie Lamort Ida Cerqua Fiorentina Roviezzo Georgios Stathopoulos Aldo Pinto Rosalinda Sorrentino Source Type: research